专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5189147A Meterodimeric T lymphocyte receptor antibody 失效
标题翻译：甲基二聚体T淋巴细胞受体抗体
公开(公告)号：US5189147A
公开(公告)日：1993-02-23
申请号：US271216
申请日：1988-11-14
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K39/00 , C07K14/725
CPC分类号： C07K14/7051 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA cones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressedThe U.S. government has rights in this invention by virtue of Grant No. NIH-5-POl-CA28900-04, NIH-5-P30-CA14051-13 and the Arthritis Foundation.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA锥来确定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

2. 发明授权

US5977321A Heterodimeric T lymphocyte receptor subunit 失效
标题翻译：异二聚体T淋巴细胞受体亚单位
公开(公告)号：US5977321A
公开(公告)日：1999-11-02
申请号：US742539
申请日：1991-08-08
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C07K16/28
CPC分类号： C07K16/2809 , C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

3. 发明授权

US4874845A T lymphocyte receptor subunit 失效
标题翻译： T淋巴细胞受体亚基
公开(公告)号：US4874845A
公开(公告)日：1989-10-17
申请号：US620122
申请日：1984-06-13
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C12N15/12
CPC分类号： C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocytes receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

4. 发明授权

US4873190A Heterodimeric T lymphocyte receptor 失效
标题翻译：异二聚体T淋巴细胞受体
公开(公告)号：US4873190A
公开(公告)日：1989-10-10
申请号：US666988
申请日：1984-10-31
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C12N15/09 , A61K39/00 , A61K39/395 , A61K45/00 , C07K14/00 , C07K14/705 , C07K14/725 , C07K16/00 , C12N5/10 , C12N15/02 , C12N15/12 , C12P21/08
CPC分类号： C07K14/7051 , A61K39/00 , Y10S930/26 , Y10S930/30
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

5. 发明授权

US5580961A Heterodimeric T lymphocyte receptor subunit 失效
标题翻译：异二聚体T淋巴细胞受体亚单位
公开(公告)号：US5580961A
公开(公告)日：1996-12-03
申请号：US210326
申请日：1994-03-18
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： C07K14/725 , C07K14/00
CPC分类号： C07K14/7051
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor submit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由可变，连接，恒定，跨膜和胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体递交的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

6. 发明授权

US4970296A Heterodimeric T lymphocyte receptor 失效
标题翻译：异二聚体T淋巴细胞受体
公开(公告)号：US4970296A
公开(公告)日：1990-11-13
申请号：US385897
申请日：1989-07-27
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K38/00 , A61K39/00 , C07K14/725
CPC分类号： C07K14/7051 , A61K38/00 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor comprising an alpha and a beta subunit. Each subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions. The two subunits are connected by a disulfide bond between cysteine residues located between the constant and transmembrane region.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor were determined using CDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.Both the T cell receptor protein and its subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了包含α和β亚基的异二聚体T淋巴细胞受体。每个亚基由信号肽，可变，连接，恒定，跨膜和细胞质区域组成。两个亚基通过位于恒定区和跨膜区之间的半胱氨酸残基之间的二硫键连接。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的CDNA克隆测定淋巴细胞受体的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体蛋白及其亚基都可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

7. 发明授权

US5882945A Heterodimeric T lymphocyte receptor 失效
标题翻译：异二聚体T淋巴细胞受体
公开(公告)号：US5882945A
公开(公告)日：1999-03-16
申请号：US262827
申请日：1994-06-21
申请人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
发明人： Haruo Saito , David M. Kranz , Herman N. Eisen , Susumu Tonegawa
IPC分类号： A61K39/00 , C07K14/725 , G01N33/531 , C07K16/28
CPC分类号： C07K14/7051 , A61K39/00
摘要： Disclosed is a heterodimeric T lymphocyte receptor subunit. The subunit consists of a signal peptide, variable, joining, constant, transmembrane, and cytoplasmic regions.The structure, amino acid, and nucleotide sequence of the lymphocyte receptor subunit were determined using cDNA clones derived from a functional murine cytotoxic T lymphocyte clone. The genes corresponding to these cDNA are expressed and rearranged specifically in T cells and have significant sequence homologies to immunoglobulin V and C genes.T cell receptor subunits may be produced from the cDNA clones. The protein molecules may be further used for the production of T-cell clone specific antibodies.
摘要翻译：公开了异二聚体T淋巴细胞受体亚基。亚基由信号肽，可变，连接，恒定，跨膜和细胞质区组成。使用衍生自功能性鼠细胞毒性T淋巴细胞克隆的cDNA克隆测定淋巴细胞受体亚基的结构，氨基酸和核苷酸序列。与这些cDNA相对应的基因在T细胞中特异性表达和重排，并且与免疫球蛋白V和C基因具有显着的序列同源性。 T细胞受体亚基可以从cDNA克隆产生。蛋白质分子可以进一步用于生产T细胞克隆特异性抗体。

8. 发明申请

US20100247552A1 PAK MODULATORS 审中-公开
标题翻译： PAK调制器
公开(公告)号：US20100247552A1
公开(公告)日：2010-09-30
申请号：US12514288
申请日：2007-11-09
申请人： Susumu Tonegawa , Mansuo L. Hayashi , Bridget Dolan
发明人： Susumu Tonegawa , Mansuo L. Hayashi , Bridget Dolan
IPC分类号： A61K39/395 , C12Q1/48 , A61K38/17 , A61K48/00 , A61K31/122 , A61K31/415 , A61P25/00 , A61P15/00 , G01N33/00 , G01N33/573 , A01K67/027
CPC分类号： A61K31/395 , A61K31/454
摘要： The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21-activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators.
摘要翻译：本发明提供了对患有易感和/或表现出一种或多种FXS和/或其他神经发育症状的患者施用p21激活的激酶（PAK）调节剂来治疗脆性X综合征和/或其它神经发育障碍的方法疾病本发明提供PAK调节剂和包含PAK调节剂的药物组合物。本发明还提供了鉴定和/或表征PAK调节剂的方法。

9. 发明申请

US20110294782A1 SMALL MOLECULE PAK INHIBITORS 审中-公开
标题翻译：小分子抑制剂
公开(公告)号：US20110294782A1
公开(公告)日：2011-12-01
申请号：US12514290
申请日：2007-11-09
申请人： Susumu Tonegawa , Mansuo L. Hayashi , Mazen Karaman , Patrick P. Zarrinkar , Daniel K. Treiber
发明人： Susumu Tonegawa , Mansuo L. Hayashi , Mazen Karaman , Patrick P. Zarrinkar , Daniel K. Treiber
IPC分类号： A61K31/553 , A61K31/496 , A61P25/00 , A61K31/4196 , A61K31/5377 , A61K31/404 , A61K31/454 , A61K31/4706
CPC分类号： A61K31/395 , A61K31/454
摘要： The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering small molecule p21-activated kinase (PAK) inhibitors to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides specific small molecule PAK inhibitors and pharmaceutical compositions comprising small molecule PAK inhibitors.
摘要翻译：本发明提供了通过向患有，易感和/或表现出一种或多种FXS和/或症状的患者施用小分子p21激活激酶（PAK）抑制剂来治疗脆弱X综合征和/或其它神经发育障碍的方法。其他神经发育障碍。本发明提供特异性的小分子PAK抑制剂和包含小分子PAK抑制剂的药物组合物。

10. 发明申请

US20110288027A1 TARGETS, METHODS, AND REAGENTS FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA 审中-公开
标题翻译：用于诊断和治疗精神病药物的目标，方法和试剂
公开(公告)号：US20110288027A1
公开(公告)日：2011-11-24
申请号：US13204245
申请日：2011-08-05
申请人： David J. Gerber , Maria Karayiorgou , Tsuyoshi Miyakawa , Susumu Tonegawa
发明人： David J. Gerber , Maria Karayiorgou , Tsuyoshi Miyakawa , Susumu Tonegawa
IPC分类号： A61K38/02 , A61K49/00 , A61P25/18 , C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/136 , C12Q2600/156
摘要： The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms linked to such genes. The invention provides oligonucleotides, arrays, and antibodies for detection of polymorphisms and variants. The invention provides transgenic mice having alterations in such genes. The invention also provides methods of treating schizophrenia by administering compounds that target these genes. The invention further provides screening methods for identifying such compounds and compounds obtained by performing the screens.
摘要翻译：本发明提供用于诊断和治疗精神分裂症及相关病症的靶标，方法和试剂。本发明通过检测钙调神经磷酸酶基因或钙调神经磷酸酶相互作用基因中的多态性，突变，变异，表达变化等，或与这些基因连锁的多态性，提供了诊断精神分裂症和精神分裂症易感性的方法。本发明提供用于检测多态性和变体的寡核苷酸，阵列和抗体。本发明提供了在这些基因中具有改变的转基因小鼠。本发明还提供了通过施用靶向这些基因的化合物来治疗精神分裂症的方法。本发明还提供了用于鉴定通过进行筛选获得的这些化合物和化合物的筛选方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式